Recent Licensing Agreement Poised to Advance Company ADC
Jan 26, 05:25 PM
Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.